10x Genomics Inc Class A TXG

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis. For more than a decade, 10x has pioneered technologies that catalyzed the single cell and spatial biology revolutions, changing how researchers measure and understand biology. Sentira extends t

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what's possible in spatial biology.

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on the company with a Buy rating.

Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index and the State Street Hea

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at 10x Genomics (NASDAQ:TXG) and the best and worst performers in the life sciences tools & services industry.

ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.

10x Genomics has delivered an unusually strong share price run over the past year, which puts a spotlight on whether the current valuation lines up with its sales base. With the stock now well above where it traded in prior years, investors are increasingly asking how much of the business story is already reflected in the price. Over the last 12 months, the stock has returned roughly 4.9x, which raises the question of how much future sales progress is already being assumed in the current...

Cathie Wood's ARK Invest funds made a broad move out of crypto-linked assets during the week, led by the sale of more than 1.5 million shares of the ARK 21Shares Bitcoin ETF.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

One portfolio shift stands out from Wood's latest moves

A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.